99久久国产免费福利-亚洲国产日韩欧美精品网站-亚洲欧美有码日韩在线播放-伊人精品无码av一区二区三区-国产精品视频九九

159-2642-3062 027-65317797
服務(wù)熱線(xiàn)（工作日：9:00-17:30）

瀏覽量: 30

  • 產(chǎn)品名稱(chēng)： Research Grade Ravulizumab ( 雷夫利珠單抗 )
  • 產(chǎn)品貨號： CSD00472
  • 貨期： 現貨
  • 價(jià)格與訂購： 2480
  • 數量：
    庫存： 100
  • 規格： 100μg
  • 產(chǎn)品信息
  • 如何訂購
    貨號（Catalog No.）
    CSD00472
    通用名INN
    Ravulizumab
    純度(Purity)
    >95%
    濃度( Concentration)
    1mg/ml
    Formulation
    PBS buffer PH7.5
    Source
    CHO cells
    內毒素(Endotoxin level)
    Please contact with the lab for this information.
    產(chǎn)品描述(Description)
    Ravulizumab is considered a long-acting complement 5 (C5) inhibitor that has been undergoing clinical trials for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) as of 4 February, 2016. A drug similar to ravulizumab (ALXN1210), called eculizumab, is currently approved for the treatment of PNH in 46 countries under the brand name Soliris?. Ravulizumab is considered by Alexion Pharmaceuticals Inc. to be a "next-generation" eculizumab molecule. Ravulizumab was subsequently approved by the US FDA in December of 2018 for a variety of beneficial characteristics that make it an advanced, next-generation agent in comparison to eculizumab. In particular, ravulizumab is currently the first and only long-acting C5 complement inhibitor that can be administered every eight weeks for the treatment of adult patients with PNH whereas eculizumab is a bi-weekly treatment,Label. Moreover, virtually all of the phase 3 trial results for ravulizumab have demonstrated the equivalent efficacy and safety established by eculizumab and that patients transition safely and effectively from using eculizumab to ravulizumab. Subsequently, whereas PNH patients may have needed to previously plan their lives rather strictly around the bi-weekly infusion administrations of eculizumab, with ravulizumab such patients can find a more relaxed dosing schedule of only six or seven infusions over an entire year,Label.
    別名(Alternative names)
    ALXN-1210,ravulizumab-cwvz
    靶點(diǎn);物種(Specificity target name;species)
    C5[Homo sapiens]
    種類(lèi)(Species)
    Humanized
    受體鑒定(Receptor identification)
    IgG2-G4-kappa
    CAS
    1803171-55-2
    存儲條件(Storage)
    Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
    Store at +4°C short term (1-2 weeks).
    Store at -20 °C 12 months.
    Store at -80°C long term.
    Note
    For research use only .